Publications by authors named "K Ring"
Quantifying ecosystem services provided by mobile species like insectivorous bats remains a challenge, particularly in understanding where and how these services vary over space and time. Bats are known to offer valuable ecosystem services, such as mitigating insect pest damage to crops, reducing pesticide use, and reducing nuisance pest populations. However, determining where bats forage is difficult to monitor.
View Article and Find Full Text PDFBackground: Ectothermic arthropods, like ticks, are sensitive indicators of environmental changes, and their seasonality plays a critical role in tick-borne disease dynamics in a warming world. Juvenile tick phenology, which influences pathogen transmission, may vary across climates, with longer tick seasons in cooler climates potentially amplifying transmission. However, assessing juvenile tick phenology is challenging in climates where desiccation pressures reduce the time ticks spend seeking blood meals.
View Article and Find Full Text PDFLong-acting antiretroviral therapy in the context of viral suppression.
Curr Opin HIV AIDS
January 2025
Article Synopsis
- Long-acting antiretroviral therapy (ART) using cabotegravir (CAB) and rilpivirine (RPV) has the potential to revolutionize HIV treatment, but its uptake remains slow in accessible countries due to operational challenges and lingering clinical questions.
- Recent clinical trials indicate that CAB+RPV injections are effective and well-tolerated, while real-world studies show high adherence and low virological failure rates in practical settings.
- Despite the low risk of virological failure, inconsistencies in defining it across studies complicate the interpretation of results, emphasizing the need for more comprehensive long-term studies in varied populations to better assess the treatment's effectiveness.
Background: Epithelial ovarian cancer (EOC) remains a significant challenge in gynecologic oncology, particularly in the context of platinum-resistant disease. Mirvetuximab soravtansine (MIRV), was approved after trials revealed favorable response and survival outcomes. MIRV targets folate receptor alpha (FRα), a cell-surface receptor that is overexpressed in EOC and has been associated with aggressive disease phenotypes.
View Article and Find Full Text PDFObjectives: Part 1 of the RUBY trial (NCT03981796) demonstrated improved survival in patients with primary advanced or recurrent endometrial cancer (EC) treated with dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel. Here, we examine additional efficacy and safety data from patients with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) EC in the RUBY trial.
Methods: Patients were randomized 1:1 to dostarlimab 500 mg or placebo plus carboplatin-paclitaxel every 3 weeks for 6 cycles followed by dostarlimab or placebo every 6 weeks for up to 3 years.